Welcome to our dedicated page for Corcept Therapeutics news (Ticker: $CORT), a resource for investors and traders seeking the latest updates and insights on Corcept Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Corcept Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Corcept Therapeutics's position in the market.
Rhea-AI Summary
Corcept Therapeutics Incorporated (NASDAQ: CORT) has appointed Roberto Vieira as President, Oncology. Vieira brings extensive experience in global commercialization of cancer medicines and building high-performing teams. He aims to lead Corcept's oncology division, initially focusing on ovarian cancer and expanding to other tumors, with a commitment to revolutionize cancer treatment through cortisol modulation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.09%
Tags
-
Rhea-AI Summary
Corcept Therapeutics Incorporated (CORT) reported preliminary, unaudited, financial results for the quarter- and year-ended December 31, 2023, provided 2024 revenue guidance, and announced a stock repurchase program. Fourth quarter revenue increased by 31% to $135.4 million, and full year 2023 revenue increased by 20% to $482.4 million. The company also announced a 2024 revenue guidance of $600 – $630 million and a $200 million stock repurchase program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.1%
Tags
-
Rhea-AI Summary
Corcept Therapeutics Incorporated (CORT) announces disappointing court decision regarding patent infringement by Teva Pharmaceuticals, plans to appeal vigorously
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.62%
Tags
Rhea-AI Summary
Corcept Therapeutics Incorporated (NASDAQ: CORT) reported a 22% increase in revenue for the third quarter of 2023, reaching $123.6 million. The company also raised its 2023 revenue guidance to $470 - $480 million. Net income per common share was $0.28 (diluted), compared to $0.30 in the same period last year. Corcept's cash and investments stood at $414.8 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.97%
Tags
-
Rhea-AI Summary
Corcept Therapeutics Incorporated has appointed Monica Tellado as President, Emerging Markets. She will be responsible for global commercial lead in therapeutics in metabolism and neurology. Corcept also announced the initiation of a Phase 2b trial of its selective cortisol modulator miricorilant and expects results from its Phase 2 DAZALS study next year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
-
Rhea-AI Summary
Corcept Therapeutics has announced the initiation of MONARCH, a Phase 2b trial of miricorilant in patients with non-alcoholic steatohepatitis (NASH). The trial will evaluate the efficacy and safety of miricorilant in adult patients with biopsy-confirmed NASH, with the primary endpoint being reduction in liver fat.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
Rhea-AI Summary
Corcept Therapeutics to report Q3 financial results and provide corporate update on November 1, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
-
Rhea-AI Summary
Corcept Therapeutics reports Q2 2023 revenue of $117.7 million, a 14% increase from Q2 2022. Raises 2023 revenue guidance to $455-$470 million. Net income per share of $0.25 (diluted). Cash and investments of $363.3 million as of June 30, 2023. Purchase of 6.6 million shares of Corcept common stock for $145.4 million. Enrollment completed in Phase 3 GRACE trial of relacorilant for Cushing's syndrome. Positive feedback on CATALYST trial. Enrollment continues in ROSELLA trial for ovarian cancer. Enrollment continues in DAZALS trial for ALS. Enrollment continues in Phase 1b trial of miricorilant for NASH. Conference call on August 2, 2023, at 5:00 p.m. Eastern Time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.91%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
News
Rhea-AI Summary
Corcept Therapeutics announces positive results from Phase 1b study of miricorilant in NASH patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
Corcept Therapeutics Inc.
Nasdaq:CORT
CORT Rankings
CORT Stock Data
2.55B
84.92M
11.41%
83.63%
20.61%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
MENLO PARK
About CORT
leading the field in the discovery of drugs that modulate the effects of cortisol the adverse effects of excess cortisol have been corcept’s focus since the company’s inception. abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol. in addition to our work with mifepristone, we have developed over 300 proprietary molecules, advancing the most promising of these to the clinic to see if they can mitigate the effects of excess cortisol and the serious, sometimes life-threatening conditions that may result. all of these compounds competitively block the glucocorticoid receptor (gr), but not the progesterone receptor. scientific literature suggests that competitive gr antagonism may have a role in treating many conditions, including post-traumatic stress disorder, mild cognitive impairment, alzheimer’s disease, alcoholis